NO910874L - Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.

Info

Publication number
NO910874L
NO910874L NO91910874A NO910874A NO910874L NO 910874 L NO910874 L NO 910874L NO 91910874 A NO91910874 A NO 91910874A NO 910874 A NO910874 A NO 910874A NO 910874 L NO910874 L NO 910874L
Authority
NO
Norway
Prior art keywords
procedure
preparation
therapeutic active
piperide
ingredients
Prior art date
Application number
NO91910874A
Other languages
English (en)
Norwegian (no)
Other versions
NO910874D0 (no
Inventor
Pascal George
Jacques Froissant
Mireille Sevrin
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of NO910874D0 publication Critical patent/NO910874D0/no
Publication of NO910874L publication Critical patent/NO910874L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO91910874A 1990-03-07 1991-03-06 Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater. NO910874L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9002855A FR2659323B1 (fr) 1990-03-07 1990-03-07 Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique.

Publications (2)

Publication Number Publication Date
NO910874D0 NO910874D0 (no) 1991-03-06
NO910874L true NO910874L (no) 1991-09-09

Family

ID=9394458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91910874A NO910874L (no) 1990-03-07 1991-03-06 Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.

Country Status (15)

Country Link
US (1) US5179108A (fi)
EP (1) EP0447292A1 (fi)
JP (1) JPH04217663A (fi)
KR (1) KR910016695A (fi)
AU (1) AU632669B2 (fi)
CA (1) CA2037610A1 (fi)
FI (1) FI911133A (fi)
FR (1) FR2659323B1 (fi)
HU (1) HUT57723A (fi)
IE (1) IE910747A1 (fi)
IL (1) IL97447A0 (fi)
NO (1) NO910874L (fi)
NZ (1) NZ237340A (fi)
PT (1) PT96952A (fi)
ZA (1) ZA911650B (fi)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681320B1 (fr) * 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
FR2701479B1 (fr) * 1993-02-11 1995-05-12 Pf Medicament Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique.
FR2769628B1 (fr) * 1997-10-09 1999-11-12 Synthelabo Derives de n-(2,3-dihydro-1h-inden-2-yl)-n-propyl-8- azabicyclo[3.2.1.]octane-3-methanamine, leur preparation et leur application en therapeutique
UA58476C2 (uk) * 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
CN100352806C (zh) * 2001-12-03 2007-12-05 弗·哈夫曼-拉罗切有限公司 作为毒蕈碱受体拮抗剂的4－哌啶基烷基胺衍生物
BR0214649A (pt) 2001-12-03 2004-11-03 Hoffmann La Roche Derivados de aminotetralina como antagonistas do receptor muscarìnico
EP1546099B1 (en) * 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
WO2006064304A1 (en) * 2004-12-15 2006-06-22 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (fi) * 1969-03-19 1971-10-20
FR2484415A1 (fr) * 1980-06-13 1981-12-18 Pharmindustrie Nouveaux derives de l'indene, procedes pour leur preparation, et leur utilisation comme medicaments
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi

Also Published As

Publication number Publication date
AU632669B2 (en) 1993-01-07
KR910016695A (ko) 1991-11-05
FR2659323A1 (fr) 1991-09-13
IE910747A1 (en) 1991-09-11
IL97447A0 (en) 1992-06-21
AU7267091A (en) 1991-09-12
JPH04217663A (ja) 1992-08-07
US5179108A (en) 1993-01-12
NO910874D0 (no) 1991-03-06
ZA911650B (en) 1991-12-24
NZ237340A (en) 1992-11-25
CA2037610A1 (en) 1991-09-08
FR2659323B1 (fr) 1992-06-12
HUT57723A (en) 1991-12-30
FI911133A0 (fi) 1991-03-06
EP0447292A1 (fr) 1991-09-18
FI911133A (fi) 1991-09-08
PT96952A (pt) 1991-10-31
HU910731D0 (en) 1991-09-30

Similar Documents

Publication Publication Date Title
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO912672L (no) Fremgangsmaate for fremstilling av terapeutisk aktive oligomerer.
NO884154L (no) Fremgangsmaate for fremstilling av terapeutisk aktive preparater.
NO903088L (no) Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
NO874869L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO902411D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-n-propylaminer.
NO883750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
NO910874L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
NO890155D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive indolpiperidin-forbindelser.
NO900919D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske etere.
NO891723D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO914071D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser
NO904800L (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamater.
NO894423D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanolaminer.
NO900972L (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO892871D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO882282L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO883959D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.
NO890724D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
NO890519D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanon-derivater.
NO891677L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenetanolamin-derivater.